Ardent Health Partners (2024 New Filing) ARDT 深 滬
已收盤 10-17 16:00:00 美东时间
14.63
+0.040
+0.27%
華盛通- 最 高14.79
- 今 開14.56
- 成交量 32.29万股
- 最 低 14.315
- 昨 收 14.59
- 總市值 20.92亿
- 52周最高 18.85
- 市盈率 靜 9.93
- 換手率 0.23%
- 52周最低 10.095
- 委 比 0.00%
- 總股本 1.43亿
- 歷史最高 20.72
- 量 比 1.14
- 振 幅 3.26%
- 歷史最低 10.095
- 每 手 1
- 風險率 1.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Breaking Down Ardent Health: 4 Analysts Share Their Views
Throughout the last three months, 4 analysts have evaluated Ardent Health (NYSE...
10-14 22:02
Goldman Sachs Initiates Coverage On Ardent Health with Neutral Rating, Announces Price Target of $19
Goldman Sachs analyst Scott Fidel initiates coverage on Ardent Health (NYSE:ARDT) with a Neutral rating and announces Price Target of $19.
10-14 20:50
Ardent Health Partners Amends Credit Agreements for Flexibility
Ardent Health Partners, Inc. ( ($ARDT) ) has shared an announcement. On Septemb...
09-24 05:14
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
UBS Initiates Coverage On Ardent Health with Buy Rating, Announces Price Target of $17
UBS analyst A.J. Rice initiates coverage on Ardent Health (NYSE:ARDT) with a Buy rating and announces Price Target of $17.
09-10 18:47
Ardent Health files $500M mixed securities shelf
Ardent Health (NYSE:ARDT) filed $500M mixed securities shelf. Filing More on Ardent Health Partners Ardent Health: The Best Prospect In An Industry That's Facing Challenges Notable analyst calls this ...
08-22 04:41
What 5 Analyst Ratings Have To Say About Ardent Health
Throughout the last three months, 5 analysts have evaluated Ardent Health (NYSE...
08-11 20:00
Keybanc Maintains Overweight on Ardent Health, Lowers Price Target to $20
Keybanc analyst Matthew Gillmor maintains Ardent Health (NYSE:ARDT) with a Overweight and lowers the price target from $24 to $20.
08-07 21:49
